Artivion (NYSE:AORT) CAO Amy Horton Sells 830 Shares of Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 830 shares of Artivion stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $29,622.70. Following the completion of the sale, the chief accounting officer owned 127,497 shares in the company, valued at approximately $4,550,367.93. This represents a 0.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Amy Horton also recently made the following trade(s):

• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The shares were sold at an average price of $37.59, for a total value of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The shares were sold at an average price of $44.42, for a total transaction of $203,088.24.

Artivion Trading Up 3.8%

NYSE AORT traded up $1.37 during trading on Thursday, hitting $37.15. The company had a trading volume of 88,842 shares, compared to its average volume of 391,103. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The company has a market cap of $1.78 billion, a price-to-earnings ratio of 186.23 and a beta of 1.59. The company’s fifty day moving average is $42.27 and its 200-day moving average is $43.08.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s revenue was up 19.2% on a year-over-year basis. On average, sell-side analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
• Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
• Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AORT. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Citizens Jmp upped their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Canaccord Genuity Group lowered their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Finally, Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd boosted its stake in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the third quarter valued at $27,000. Larson Financial Group LLC boosted its position in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares during the last quarter. USA Financial Formulas increased its holdings in Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.